Health
GC Pharma sticks to plasma therapy study despite global trial failures – Korea Biomedical Review
GC Pharma said it would continue to develop hyperimmune globulin drug for Covid-19 despite the recent statement by CoVig-19 Plasma Alliance that it confirmed disappointing…
GC Pharma said it would continue to develop hyperimmune globulin drug for Covid-19 despite the recent statement by CoVig-19 Plasma Alliance that it confirmed disappointing results in phase 3 clinical trials.
Takeda, one of the co-leaders of the CoVig-19 Plasma Alliance, said Wednesday that the group has completed the phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trials and decided to end the year-long collaboration as it did not meet the endpoint in the study.
…
-
Business23 hours agoWhat Warren Buffett’s farewell letter means for Berkshire Hathaway investors
-
General23 hours agoEnvironment Bill passes Senate as Greens cut deal with Labor
-
General22 hours agoCalls for states to change alcohol laws ahead of women’s ministers meeting
-
General20 hours agoCool weather sets cherry crops ‘weeks’ behind schedule in lead-up to Christmas